Moderna sues Pfizer/BioNTech for patent infringement over Covid vaccine | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Tuesday
December 05, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
TUESDAY, DECEMBER 05, 2023
Moderna sues Pfizer/BioNTech for patent infringement over Covid vaccine

World+Biz

Reuters
26 August, 2022, 06:55 pm
Last modified: 26 August, 2022, 06:58 pm

Related News

  • Pfizer cuts earnings outlook on lower Covid-19 drug sales
  • Moderna ties up with Immatics to boost cancer vaccine development
  • Moderna says updated Covid vaccine is effective against newer variant
  • Pfizer's updated Covid shot effective against 'Eris' variant in mice study
  • US FDA approves Pfizer's blood cancer therapy

Moderna sues Pfizer/BioNTech for patent infringement over Covid vaccine

Reuters
26 August, 2022, 06:55 pm
Last modified: 26 August, 2022, 06:58 pm
FILE PHOTO: Vials with a sticker reading "Covid-19/Coronavirus vaccine/Injection only" and a syringe are seen in front of a displayed Moderna logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
FILE PHOTO: Vials with a sticker reading "Covid-19/Coronavirus vaccine/Injection only" and a syringe are seen in front of a displayed Moderna logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.

Pfizer shares fell 1.4% before the bell while BioNTech was down about 2%.

The lawsuit, which seeks undetermined monetary damages, was being filed in U.S. District Court in Massachusetts and the Regional Court of Dusseldorf in Germany, Moderna said in a news release on Friday.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic," Moderna Chief Executive Stephane Bancel said in the statement.

Moderna Inc (MRNA.O), on its own, and the partnership of Pfizer Inc (PFE.N) and BioNTech SE (22UAy.DE) were two of the first groups to develop a vaccine for the novel coronavirus.

Just a decade old, Moderna, based in Cambridge, Massachusetts, had been an innovator in the messenger RNA (mRNA) vaccine technology that enabled the unprecedented speed in developing the COVID-19 vaccine.

An approval process that previously took years was completed in months, thanks largely to the breakthrough in mRNA vaccines, which teach human cells how to make a protein that will trigger an immune response.

Germany-based BioNTech had also been working in this field when it partnered with the U.S. pharma giant Pfizer.

The U.S. Food and Drug Administration granted emergency use authorization for the COVID-19 vaccine first to Pfizer/BioNTech in December 2020, then one week later to Moderna.

Moderna's COVID vaccine - its lone commercial product - has brought in $10.4 billion in revenue this year while Pfizer's vaccine brought in about $22 billion.

Moderna alleges Pfizer/BioNTech, without permission, copied mRNA technology that Moderna had patented between 2010 and 2016, well before COVID-19 emerged in 2019 and exploded into global consciousness in early 2020.

Early in the pandemic, Moderna said it would not enforce its COVID-19 patents to help others develop their own vaccines, particularly for low- and middle-income countries. But in March 2022 Moderna said it expected companies such as Pfizer and BioNTech to respect its intellectual property rights. It said it would not seek damages for any activity before March 8, 2022.

Patent litigation is not uncommon in the early stages of new technology.

Pfizer and BioNTech are already facing multiple lawsuits from other companies who say the partnership's vaccine infringes on their patents. Pfizer/BioNTech have said they will defend their patents vigorously.

Germany's CureVac , for instance, also filed a lawsuit against BioNTech in Germany in July. BioNTech responded in a statement that its work was original.

Moderna has also been sued for patent infringement in the United States and has an ongoing dispute with the U.S. National Institutes of Health over rights to mRNA technology.

In Friday's statement, Moderna said Pfizer/BioNTech appropriated two types of intellectual property.

One involved an mRNA structure that Moderna says its scientists began developing in 2010 and were the first to validate in human trials in 2015.

"Pfizer and BioNTech took four different vaccine candidates into clinical testing, which included options that would have steered clear of Moderna's innovative path. Pfizer and BioNTech, however, ultimately decided to proceed with a vaccine that has the same exact mRNA chemical modification to its vaccine," Moderna said in its statement.

The second alleged infringement involves the coding of a full-length spike protein that Moderna says its scientists developed while creating a vaccine for the coronavirus that causes Middle East Respiratory Syndrome (MERS).

Although the MERS vaccine never went to market, its development helped Moderna rapidly roll out its COVID-19 vaccine.

Pfizer said the company had not been served and that they were unable to comment at this time.

Top News

Moderna / Pfizer

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Record 27% nominations scrapped with  more bigshots rejected
    Record 27% nominations scrapped with  more bigshots rejected
  • Bolivian President Hugo Banzer shakes hands with Victor Manuel Rocha, the then U.S. Ambassador to Bolivia, during a ceremony in the Goverment Palace in La Paz, August 3, 2000. File photo DM/JP/HB, Routers
    US charges ex-ambassador with spying for Cuba over decades
  • A brain drain query: Why do they leave?
    A brain drain query: Why do they leave?

MOST VIEWED

  • LPG cylinders. Photo: Courtesy
    12kg LPG cylinder price up Tk23
  • For the first time, Bangladesh seeks foreign loans to support Rohingyas
    For the first time, Bangladesh seeks foreign loans to support Rohingyas
  • Photo: Collected
    Indonesia volcano erupts, spews ash 3 km into sky
  • External trade through Islamic banks in decline
    External trade through Islamic banks in decline
  • Halal products export receives boost with new policy, but more is required
    Halal products export receives boost with new policy, but more is required
  • Exports up 27% in Nov as peak festival sales begin in West
    Exports up 27% in Nov as peak festival sales begin in West

Related News

  • Pfizer cuts earnings outlook on lower Covid-19 drug sales
  • Moderna ties up with Immatics to boost cancer vaccine development
  • Moderna says updated Covid vaccine is effective against newer variant
  • Pfizer's updated Covid shot effective against 'Eris' variant in mice study
  • US FDA approves Pfizer's blood cancer therapy

Features

A brain drain query: Why do they leave?

A brain drain query: Why do they leave?

31m | Panorama
The school has been flooding since June 2007 and the water level is rising every year. PHOTO: COURTESY

Will Dubai pay heed to the suffering of Sultan Al Nahyan School students in Bangladesh?

36m | Panorama
Masud Ahmad has written one of the finest Bangla novels in recent times, titled ‘Kanchanfuler Kobi,’ centred around the life and works of eminent poet Jibanananda Das. Photo: Rajib Dhar

How little-known Masud Ahmad became the 'Shera Bangali'

1d | Panorama
Designed for utility, the D90 is a giant in comparison to other MG models and misses out on design elements which gives the other models their sporty stance. Photo: Akif Hamid

Maxus D90: Spacious, capable and practical

1d | Wheels

More Videos from TBS

Despite the incentives, remittances are not speeding up

Despite the incentives, remittances are not speeding up

12h | TBS Economy
Terrible Torture in Israeli Prisons: Testimony of Prisoners

Terrible Torture in Israeli Prisons: Testimony of Prisoners

10h | TBS World
Lighterage ship trips halved

Lighterage ship trips halved

12h | TBS Economy
3 commercial ships hit by missiles in Houthi attack in Red Sea

3 commercial ships hit by missiles in Houthi attack in Red Sea

13h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net